Menu
Many developed countries, including the US, UK, Germany, and the UAE, have established national population genomics programs, while progressive emerging markets, such as Singapore and India, have recently initiated similar programs. The aim of a National Population Genomics Project is to build a library of the nation’s unique ethnic and population-based genetic information, which has multiple benefits, including the creation of a national reference genome that is vital for developing precision medicine specific for a country’s population.
Establishing a genomics database allows nations to contribute to global representative data sets utilised for drug discovery, drug trials, and real-world evidence-based studies, among other purposes. This data can be instrumental in analysing how approved drugs perform in real world scenarios and conducting health economics studies. Local researchers can greatly benefit from access to this national database, propelling local R&D efforts. A prime example of this is China, where research initiatives have flourished after the availability of such data, giving local efforts a competitive advantage in terms of data accessibility.
A national genomics library can empower a country to regulate drugs entering the market more efficiently by requiring pharmaceutical companies to test drugs against this national database. This could allow for early detection of adverse drug reactions, improved patient outcomes, and significant national revenue as pharmaceutical companies would need to license this data from the government repeatedly. The potential steady return from this licensing helps make the initial investment into such a program financially viable. Other revenue streams could result from inclusion in drug trial programs, real-world evidence studies, and collaborations with research and academic organisations, further supporting early adoption of such programs.
Moreover, as the medical field transitions towards precision medical care, the availability of genetic data signifies a fundamental step towards curated healthcare. A country investing early in genetic testing facilities can accelerate its adoption of future precision medicine treatments, potentially leading to improved health outcomes and associated economic impacts. Expected savings for a country that pursues precision medicine approaches enabled by genomics can expect to save between 5% and 10% of their current healthcare expenditures at a national level.
In a two-phase approach to establishing a National Genomics Program, Xeomics initially collaborates with a government for a pilot program to prove the concept’s viability, gauging the necessary resources for full-scale implementation. Following this, a consortium of industry leaders will roll out the full-scale program, creating essential facilities ranging from testing sites to data storage and research ventures. Funding for such programs typically ranges between USD 50 million to over USD 1 billion, based on population and objectives. Funding routes include direct government investment, collaboration through public-private partnerships, or a long-term soft loan setup with Xeomics overseeing the project. Regardless of the financing method, data ownership remains with the respective government. Xeomics is dedicated to aiding in both financing and execution, keen on partnering locally to ensure a program’s success.
For additional information please email us at: info@xeomics.com